In this piece, we will take a look at the top five best stocks to buy under $20 according to Jeremy Green’s Redmile Group. If you want an introduction to the hedge fund investor and his firm, then head on over to the 10 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group.
5. Replimune Group, Inc. (NASDAQ:REPL)
Redmile Group Stake Value: $104 million
Percentage of Redmile Group’s 13F Portfolio: 2.38%
Number of Hedge Fund Holders: 11
Price per Share as of April 28, 2022: $16.8
Replimune Group, Inc. (NASDAQ:REPL) is an American biotechnology firm headquartered in Woburn, Massachusetts. It develops treatments for cancer that use the body’s natural immune system to fight against the often deadly disease.
Redmile Group owned 3.8 million Replimune Group, Inc. (NASDAQ:REPL) shares as the fourth quarter of last year came to an end. These were worth $104 million. During the same time period, 11 of the 924 hedge funds polled by Insider Monkey had invested in the company.
Replimune Group, Inc. (NASDAQ:REPL) reported -$0.57 EPS at the end of its fiscal third quarter, beating analyst estimates by a hairline. The company’s cash reserves stood at $420 million by December 2021, marking a drop from the end of March 2021. BMO Capital reduced its price target to $30 from $51 in March 2022, noting reduced probabilities for a treatment’s success.
Mark Lampert’s Biotechnology Value Fund / BVF Inc is Replimune Group, Inc. (NASDAQ:REPL)’s largest investor after Redmile Group through a $25 million stake that comes via 926,529 shares.
4. The Beauty Health Company (NASDAQ:SKIN)
Redmile Group Stake Value: $122.8 million
Percentage of Redmile Group’s 13F Portfolio: 2.79%
Number of Hedge Fund Holders: 23
Price per Share as of April 28, 2022: $13.28
The Beauty Health Company (NASDAQ:SKIN) is an American household and personal products company headquartered in Long Beach, California. The company provides several skincare products alongside a software application for skin health.
For its fiscal Q4, The Beauty Health Company (NASDAQ:SKIN) had brought in $77.9 million in revenue and -$0.12 in GAAP EPS, beating analyst revenue estimates but missing them for EPS. Stifel set a $33 price target for the company in April 2022, stating that the company has strong growth ahead of it and the stock price is overly negative.
Mr. Green’s hedge fund held a $122 million stake in The Beauty Health Company (NASDAQ:SKIN) as part of its Q4 2021 investment portfolio. This came in the form of 5 million shares. During the same time period, 23 of the 924 hedge funds polled by Insider Monkey had invested in the company.
The Beauty Health Company (NASDAQ:SKIN)’s largest investor after Redmile Group is Christian Leone’s Luxor Capital Group which owns 4 million shares worth $99 million.
3. ADC Therapeutics SA (NYSE:ADCT)
Redmile Group Stake Value: $150.5 million
Percentage of Redmile Group’s 13F Portfolio: 3.42%
Number of Hedge Fund Holders: 5
Price per Share as of April 28, 2022: $11.72
ADC Therapeutics SA (NYSE:ADCT) is a Switzerland-based biotechnology firm. It develops treatments for blood malignancies and solid tumors such as large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), and follicular lymphoma.
Redmile Group owned 7.4 million ADC Therapeutics SA (NYSE:ADCT) shares by the end of the December 2021 quarter. These were worth $150 million. Insider Monkey’s Q4 2021 profiling of 924 hedge funds outlined that 5 had invested in the company.
ADC Therapeutics SA (NYSE:ADCT) raked in $17 million in revenue and -$0.39 in non-GAAP EPS for its fiscal fourth quarter, beating analyst estimates for both. Cantor Fitzgerald lowered its price target to $26 from $45 in March 2022, justifying the decision by stating that it is on the lookout for more results from a treatment.
Lei Zhang’s Hillhouse Capital Management is ADC Therapeutics SA (NYSE:ADCT)’s largest investor after Mr. Green’s firm. It has a $10 million stake that comes through holding 500,000 shares.
2. Science 37 Holdings, Inc. (NASDAQ:SNCE)
Redmile Group Stake Value: $247 million
Percentage of Redmile Group’s 13F Portfolio: 5.61%
Number of Hedge Fund Holders: 12
Price per Share as of April 28, 2022: $3.97
Science 37 Holdings, Inc. (NASDAQ:SNCE) is an American health information services provider that is headquartered in Research Triangle Park, North Carolina. The company’s platform allows healthcare providers and personnel to combine their information and expertise.
As its fiscal fourth quarter came to an end, Science 37 Holdings, Inc. (NASDAQ:SNCE) had posted $20 million in revenue and -$0.60 in GAAP EPS, beating analyst revenue estimates but missing them for EPS. The company published new therapeutic data from a survey in March 2022, that demonstrated the strength and benefits of its platform.
Mr. Green’s investment firm owned a $247 million stake in Science 37 Holdings, Inc. (NASDAQ:SNCE) by the end of Q4 2021. This came in the form of 19.8 million shares. During the same time period, 12 of the 924 hedge funds part of Insider Monkey’s survey had invested in the company.
1. Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Redmile Group Stake Value: $262 million
Percentage of Redmile Group’s 13F Portfolio: 5.96%
Number of Hedge Fund Holders: 23
Price per Share as of April 28, 2022: $7.26
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is an American biotechnology firm based in Philadelphia, Pennsylvania. It develops and designs treatments for rare diseases such as Fabry disease, Pompe disease, and a protein regulating brain development.
Redmile Group’s fourth quarter of 2021 stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) was worth $262 million and it came in the form of the firm owning 22 million shares. Insider Monkey’s Q4 2021 research covering 924 hedge funds revealed that 23 had invested in the firm.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted $305 million in revenue and -$0.92 in GAAP EPS for its latest fiscal year, missing analyst estimates for both metrics. Goldman Sachs set an $11 price target for the company in April 2022, sharing that the company can do more on commercial execution.
Joseph Edelman’s Perceptive Advisors is Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s largest investor. It owns 26 million shares that are worth $306 million.
Disclosure: None. You can also take a look at 10 Best Stocks To Buy and Hold For 5 Years and 10 Dividend Aristocrats to Buy for 2022.
